Matches in DBpedia 2016-04 for { <http://wikidata.dbpedia.org/resource/Q17143508> ?p ?o }
Showing triples 1 to 40 of
40
with 100 triples per page.
- Q17143508 subject Q6762709.
- Q17143508 abstract "Catabasis Pharmaceuticals, founded in 2008 and based in Cambridge, Mass., is a clinical-stage biopharmaceutical company developing bi-functional small molecules for treatment of dyslipidemias and inflammatory diseases. The company’s drug development programs are based on the principles of pathway pharmacology to treat diseases by modulating more than one target in a disease pathway simultaneously. Catabasis uses a proprietary linker technology to conjugate two drugs that act on different nodes of a disease pathway, with the intent of improving safety and efficacy of the two components. The conjugate is designed to keep the linked components inactive in plasma until they are cleaved by a specific class of intracellular enzymes, releasing both bioactives within the cells of target tissues.Catabasis has two programs in clinical development. CAT-2003, a conjugate of the B vitamin niacin and the omega-3 fatty acid eicosapentaenoic acid (EPA), is designed to treat severe hypertriglyceridemia and other lipid disorders and is currently in clinical testing. CAT-1004, a conjugate of the omega-3 fatty acid docosahexaenoic acid (DHA) and salicylate, has completed Phase 1 testing; the drug is being developed for the treatment of inflammatory diseases such as inflammatory bowel disease and Duchenne muscular dystrophy. In the Phase 1 study, results showed that CAT-1004 was safe and well tolerated,and that the linker technology allowed the active components to inhibit the NF-kB pathway synergistically;, this pathway plays an important role in inflammation.".
- Q17143508 industry Q12140.
- Q17143508 location Q49111.
- Q17143508 numberOfEmployees "34".
- Q17143508 type Q891723.
- Q17143508 wikiPageExternalLink www.catabasis.com.
- Q17143508 wikiPageWikiLink Q101991.
- Q17143508 wikiPageWikiLink Q12140.
- Q17143508 wikiPageWikiLink Q134658.
- Q17143508 wikiPageWikiLink Q1467339.
- Q17143508 wikiPageWikiLink Q1476525.
- Q17143508 wikiPageWikiLink Q1648484.
- Q17143508 wikiPageWikiLink Q191756.
- Q17143508 wikiPageWikiLink Q193572.
- Q17143508 wikiPageWikiLink Q409990.
- Q17143508 wikiPageWikiLink Q411114.
- Q17143508 wikiPageWikiLink Q423345.
- Q17143508 wikiPageWikiLink Q49111.
- Q17143508 wikiPageWikiLink Q6762709.
- Q17143508 wikiPageWikiLink Q891723.
- Q17143508 wikiPageWikiLink Q917447.
- Q17143508 homepage www.catabasis.com.
- Q17143508 industry Q12140.
- Q17143508 location Q49111.
- Q17143508 name "Catabasis Pharmaceuticals".
- Q17143508 numEmployees "34".
- Q17143508 type Q891723.
- Q17143508 type Organization.
- Q17143508 type Agent.
- Q17143508 type Company.
- Q17143508 type Organisation.
- Q17143508 type Agent.
- Q17143508 type SocialPerson.
- Q17143508 type Thing.
- Q17143508 type Q43229.
- Q17143508 comment "Catabasis Pharmaceuticals, founded in 2008 and based in Cambridge, Mass., is a clinical-stage biopharmaceutical company developing bi-functional small molecules for treatment of dyslipidemias and inflammatory diseases. The company’s drug development programs are based on the principles of pathway pharmacology to treat diseases by modulating more than one target in a disease pathway simultaneously.".
- Q17143508 label "Catabasis Pharmaceuticals".
- Q17143508 homepage www.catabasis.com.
- Q17143508 name "Catabasis Pharmaceuticals".